RE:In talks with AstraZeneca with Revenue 22.46 billion yearThank you for this allain250.
With ongoing negotiations at this time, ICO must be reaching a very important drug development milestone for Oral B Amphotericin. Looks like all the testing and trial results may be ready for compilation into a technical report for review by potential partners such as AstraZeneca prior to FDA approval. Perhaps approval in Australia will pave the way for approval by the FDA too.
AstraZeneca may not be the only big pharma company that ICO is in talks with, but it is logical to think that the company that has the best laboratories and production facilities will win the contract to produce, distribute, and market globally. ICO would hold all the patent rights, and therefore be the one to grant the license to produce, market and distribute Oral B Amphotericin.
Congratulations on your purchases today. It looks like the seller from TD may be a shorty who is likely to get his knickers in a knot when the stock is halted.
I don't want to be near him when he is caught naked, with his soiled shorts worn on his head.
The fundamental case for investment here is very bullish, but until the hostile bid is launched, pressure will continue to keep the stock down, so accumulation at this time is auspicious.
DOC.